

# Colm Bergin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5578681/publications.pdf>

Version: 2024-02-01

102  
papers

5,130  
citations

218381

26  
h-index

95083

68  
g-index

103  
all docs

103  
docs citations

103  
times ranked

8561  
citing authors

#	ARTICLE	IF	CITATIONS
1	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 161-176.	3.7	1,619
2	Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. <i>PLoS ONE</i> , 2020, 15, e0240784.	1.1	634
3	COVID19 coagulopathy in Caucasian patients. <i>British Journal of Haematology</i> , 2020, 189, 1044-1049.	1.2	307
4	Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV/HCV International Panel. <i>Aids</i> , 2002, 16, 813-828.	1.0	280
5	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2546-2553.	1.9	208
6	Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. <i>Annals of the American Thoracic Society</i> , 2021, 18, 997-1003.	1.5	202
7	Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1064-1070.	1.9	142
8	Role of Comorbidity in Mortality Related to Staphylococcus aureus Bacteremia: A Prospective Study Using the Charlson Weighted Index of Comorbidity. <i>Infection Control and Hospital Epidemiology</i> , 2003, 24, 890-896.	1.0	140
9	Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. <i>British Journal of Haematology</i> , 2021, 192, 714-719.	1.2	92
10	More on COVID-19 coagulopathy in Caucasian patients. <i>British Journal of Haematology</i> , 2020, 189, 1060-1061.	1.2	73
11	Fatigue following COVID-19 infection is not associated with autonomic dysfunction. <i>PLoS ONE</i> , 2021, 16, e0247280.	1.1	68
12	Elevated Serum Levels of Interferon-Inducible Protein 10 in Patients Coinfected with Hepatitis C Virus and HIV. <i>Journal of Infectious Diseases</i> , 2007, 196, 1053-1057.	1.9	67
13	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1914-1921.	1.9	58
14	Absence of Opioid Withdrawal Symptoms in Patients Receiving Methadone and the Protease Inhibitor Lopinavir/Ritonavir. <i>Clinical Infectious Diseases</i> , 2002, 34, 1143-1145.	2.9	55
15	Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa071.	0.9	54
16	Healthcare-Associated Staphylococcus aureus Bacteremia and the Risk for Methicillin Resistance: Is the Centers for Disease Control and Prevention Definition for Community-Acquired Bacteremia Still Appropriate?. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 204-209.	1.0	53
17	Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet HIV</i> , 2021, 8, e397-e407.	2.1	42
18	Opt-Out Panel Testing for HIV, Hepatitis B and Hepatitis C in an Urban Emergency Department: A Pilot Study. <i>PLoS ONE</i> , 2016, 11, e0150546.	1.1	39

#	ARTICLE	IF	CITATIONS
19	HIV-1 Promotes the Degradation of Components of the Type 1 IFN JAK/STAT Pathway and Blocks Anti-viral ISG Induction. <i>EBioMedicine</i> , 2018, 30, 203-216.	2.7	37
20	Serological markers of SARS-CoV-2 infection; anti-nucleocapsid antibody positivity may not be the ideal marker of natural infection in vaccinated individuals. <i>Journal of Infection</i> , 2021, 83, e9-e10.	1.7	37
21	Usage of unscheduled hospital care by homeless individuals in Dublin, Ireland: a cross-sectional study. <i>BMJ Open</i> , 2017, 7, e016420.	0.8	36
22	The effects of a 16-week aerobic exercise programme on cognitive function in people living with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 667-674.	0.6	35
23	Telementoring with project ECHO: a pilot study in Europe. <i>BMJ Innovations</i> , 2017, 3, 144-151.	1.0	35
24	Possibility and agency in Figured Worlds: becoming a "good doctor". <i>Medical Education</i> , 2017, 51, 248-257.	1.1	33
25	Longitudinal Analysis of COVID-19 Patients Shows Age-Associated T Cell Changes Independent of Ongoing Ill-Health. <i>Frontiers in Immunology</i> , 2021, 12, 676932.	2.2	33
26	Reliability and validity of a new HIV-specific questionnaire with adults living with HIV in Canada and Ireland: the HIV Disability Questionnaire (HDQ). <i>Health and Quality of Life Outcomes</i> , 2015, 13, 124.	1.0	32
27	Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. <i>PLoS ONE</i> , 2014, 9, e94495.	1.1	32
28	Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1150-1154.	1.1	30
29	Outcomes from a large 10 year hepatitis C treatment programme in people who inject drugs: No effect of recent or former injecting drug use on treatment adherence or therapeutic response. <i>PLoS ONE</i> , 2017, 12, e0178398.	1.1	29
30	Thalidomide Therapy for the Treatment of Hypertrophic Herpes Simplex Virus-Related Genitalis in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2007, 44, e96-e99.	2.9	26
31	Impact of a new vaccine clinic on hepatitis B vaccine completion and immunological response rates in an HIV-positive cohort. <i>Journal of Infection and Public Health</i> , 2013, 6, 173-178.	1.9	26
32	The Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. <i>Clinical Infectious Diseases</i> , 2013, 56, 228-235.	2.9	24
33	Prevalence of antibodies to SARS-CoV-2 in Irish hospital healthcare workers. <i>Epidemiology and Infection</i> , 2021, 149, e157.	1.0	23
34	IFNL cytokines do not modulate human or murine NK cell functions. <i>Human Immunology</i> , 2014, 75, 996-1000.	1.2	22
35	Antimicrobial stewardship challenges and innovative initiatives in the acute hospital setting during the COVID-19 pandemic. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 272-275.	1.3	22
36	Interferon Gamma Release Assays for the Diagnosis of Latent TB Infection in HIV-Infected Individuals in a Low TB Burden Country. <i>PLoS ONE</i> , 2013, 8, e53330.	1.1	21

#	ARTICLE	IF	CITATIONS
37	JC virus in the Irish population: Significant increase of genotype 2 in immunocompromised individuals. <i>Journal of NeuroVirology</i> , 2006, 12, 39-46.	1.0	20
38	Baseline Prevalence and Emergence of Protease Inhibitor Resistance Mutations following Treatment in Chronic HCV Genotype-1-Infected Individuals. <i>Antiviral Therapy</i> , 2015, 20, 865-869.	0.6	19
39	Continuing professional development and Irish hospital doctors: a survey of current use and future needs. <i>Clinical Medicine</i> , 2017, 17, 307-315.	0.8	19
40	Intracellular Indinavir Pharmacokinetics in HIV-Infected Patients: Comparison with Plasma Pharmacokinetics. <i>Antiviral Therapy</i> , 2003, 8, 191-198.	0.6	19
41	Phenotypic Characterization of Lymphocytes in HCV/HIV Co-infected Patients. <i>Viral Immunology</i> , 2009, 22, 39-48.	0.6	17
42	Late HIV presentation – missed opportunities and factors associated with a changing pattern over time. <i>International Journal of STD and AIDS</i> , 2017, 28, 814-821.	0.5	17
43	Control of HIV infection by IFN- $\lambda$ : implications for latency and a cure. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 775-783.	2.4	17
44	SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays. <i>Microbiology Spectrum</i> , 2021, 9, e0039121.	1.2	17
45	Severe COVID-19 is characterised by inflammation and immature myeloid cells early in disease progression. <i>Heliyon</i> , 2022, 8, e09230.	1.4	16
46	Six Lessons for COVID-19 Rehabilitation From HIV Rehabilitation. <i>Physical Therapy</i> , 2020, 100, 1906-1909.	1.1	15
47	Prevalence of Antibodies to SARS-CoV-2 Following Natural Infection and Vaccination in Irish Hospital Healthcare Workers: Changing Epidemiology as the Pandemic Progresses. <i>Frontiers in Medicine</i> , 2021, 8, 758118.	1.2	15
48	Evolution of an International Research Collaborative in HIV and Rehabilitation: Community Engaged Process, Lessons Learned, and Recommendations. <i>Progress in Community Health Partnerships: Research, Education, and Action</i> , 2018, 12, 395-408.	0.2	15
49	High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: Results of the Irish Early Access Programme. <i>Journal of Hepatology</i> , 2016, 65, 446-448.	1.8	14
50	Opt-out testing for blood-borne viruses in primary care: a multicentre, prospective study. <i>British Journal of General Practice</i> , 2016, 66, e392-e396.	0.7	14
51	Long COVID and episodic disability: advancing the conceptualisation, measurement and knowledge of episodic disability among people living with Long COVID – protocol for a mixed-methods study. <i>BMJ Open</i> , 2022, 12, e060826.	0.8	13
52	Syphilis consequences and implications in delayed diagnosis: five cases of secondary syphilis presenting with ocular symptoms. <i>Sexually Transmitted Infections</i> , 2010, 86, 512-513.	0.8	12
53	Variation in Both IL28B and KIR2DS3 Genes Influence Pegylated Interferon and Ribavirin Hepatitis C Treatment Outcome in HIV-1 Co-Infection. <i>PLoS ONE</i> , 2013, 8, e66831.	1.1	12
54	Treatment of Kaposi's sarcoma with liposomal doxorubicin. <i>American Journal of Health-System Pharmacy</i> , 1995, 52, 2001-2004.	0.5	11

#	ARTICLE	IF	CITATIONS
55	A High Prevalence Rate of a Positive Screen for Cognitive Impairment in Patients With Human Immunodeficiency Virus Attending an Irish Clinic. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofw242.	0.4	11
56	Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. <i>Viruses</i> , 2021, 13, 1371.	1.5	11
57	Generic substitution of antiretrovirals: patients' and health care providers' opinions. <i>International Journal of STD and AIDS</i> , 2017, 28, 1239-1246.	0.5	10
58	Opt-out screening for HIV, hepatitis B and hepatitis C: observational study of screening acceptance, yield and treatment outcomes. <i>Emergency Medicine Journal</i> , 2020, 37, 102-105.	0.4	9
59	Improved diagnosis of SARS-CoV-2 by using nucleoprotein and spike protein fragment 2 in quantitative dual ELISA tests. <i>Epidemiology and Infection</i> , 2021, 149, e140.	1.0	9
60	Prevalence of smell and taste dysfunction in a cohort of COVID19 outpatients managed through remote consultation from a large urban teaching hospital in Dublin, Ireland. <i>Infection Prevention in Practice</i> , 2020, 2, 100076.	0.6	8
61	Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV/HCV-coinfected patients. <i>Antiviral Therapy</i> , 2011, 16, 1237-1247.	0.6	7
62	Human Papillomavirus (HPV) and the Usefulness of the HPV Vaccine for Men Who Have Sex With Men. <i>Journal of Infectious Diseases</i> , 2014, 210, 1679-1679.	1.9	7
63	High levels of susceptibility to measles, mumps and rubella (MMR) in HIV-infected individuals in Ireland. <i>Journal of Infection</i> , 2016, 73, 84-86.	1.7	7
64	Seroepidemiology of hepatitis A, hepatitis B and varicella virus in people living with HIV in Ireland. <i>Journal of Infection and Public Health</i> , 2017, 10, 888-890.	1.9	7
65	To Induce Immune Reconstitution Inflammatory Syndrome or Suppress It: The Spectrum of <i>Mycobacterium genavense</i> in the Antiretroviral Era. <i>Clinical Infectious Diseases</i> , 2021, 72, 315-318.	2.9	7
66	SARS-CoV-2 anti-nucleocapsid assay performance in healthcare workers at baseline and 6 months. <i>Irish Journal of Medical Science</i> , 2022, 191, 1089-1092.	0.8	7
67	Documented Prevalence of HIV Type 1 Antiretroviral Transmitted Drug Resistance in Ireland from 2004 to 2008. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 276-281.	0.5	6
68	Development of chronic hepatitis B infection in a hepatitis B vaccine responder. <i>International Journal of STD and AIDS</i> , 2017, 28, 526-528.	0.5	6
69	Seizures in HIV: The case for special consideration. <i>Epilepsy &amp; Behavior Case Reports</i> , 2018, 10, 38-43.	1.5	6
70	Malarial cases presenting to a European urban Emergency Department. <i>European Journal of Emergency Medicine</i> , 2013, 20, 115-119.	0.5	5
71	Acceptability of and symptom findings from an online symptom check-in tool for COVID-19 outpatient follow-up among a predominantly healthcare worker population. <i>BMJ Open</i> , 2021, 11, e050444.	0.8	5
72	Disability and self-care living strategies among adults living with HIV during the COVID-19 pandemic. <i>AIDS Research and Therapy</i> , 2021, 18, 87.	0.7	5

#	ARTICLE	IF	CITATIONS
73	Study protocol for the 'St James's Hospital, Tallaght University Hospital, Trinity College Dublin Allied Researchers' (STTAR) Bioresource for COVID-19. HRB Open Research, 0, 5, 20.	0.3	5
74	Cross-cultural applicability of the episodic disability framework with adults living with HIV in Ireland: a qualitative study. Disability and Rehabilitation, 2021, 43, 229-240.	0.9	4
75	Human Immunodeficiency Virus Type 1 in Ireland: Phylogenetic Evidence for Risk Group-Specific Subepidemics. AIDS Research and Human Retroviruses, 2012, 28, 1073-1081.	0.5	3
76	Factors associated with non-retention in HIV care in an era of widespread antiretroviral therapy. International Journal of STD and AIDS, 2017, 28, 679-684.	0.5	3
77	Improvement in cognitive impairment following a 12-week aerobic exercise intervention in individuals with non-irrhrotic chronic hepatitis C. Journal of Viral Hepatitis, 2021, 28, 637-650.	1.0	3
78	NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient. Journal of Clinical Virology, 2016, 82, 66-69.	1.6	2
79	High-Cost, High-Need Users of Acute Unscheduled HIV Care: A Cross-Sectional Study. Open Forum Infectious Diseases, 2020, 7, ofaa037.	0.4	2
80	Successful Treatment of Cryptococcal Meningitis and Cryptococcoma with Isavuconazole in a Patient Living with HIV. Journal of Fungi (Basel, Switzerland), 2021, 7, 425.	1.5	2
81	Reply to Calcagno et al. Clinical Infectious Diseases, 2013, 56, 1678-1679.	2.9	1
82	Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme. Journal of Infection, 2015, 71, 675-682.	1.7	1
83	Pharmacist-led pre-treatment assessment, management and outcomes in a Hepatitis C treatment patient cohort. International Journal of Clinical Pharmacy, 2019, 41, 1227-1238.	1.0	1
84	Opt-out bloodborne virus screening: a cross-sectional observational study in an acute medical unit. BMJ Open, 2019, 9, e022777.	0.8	1
85	Anal cancer in people living with HIV: A case series. International Journal of STD and AIDS, 2020, 31, 82-84.	0.5	1
86	Evaluating patient attitudes to increased patient engagement with antimicrobial stewardship: a quantitative survey. JAC-Antimicrobial Resistance, 2020, 2, dlaa046.	0.9	1
87	First International Congress on Drug Therapy and HIV Infection.. Journal of the European Academy of Dermatology and Venereology, 1993, 2, 149-150.	1.3	0
88	Progressive multifocal leukoencephalopathy – Experimental options. European Journal of Internal Medicine, 2009, 20, e142.	1.0	0
89	Varicella infection and the impact of late entry into the Irish healthcare system. Journal of Infection and Public Health, 2010, 3, 106-112.	1.9	0
90	Retention in Human Immunodeficiency Virus (HIV) Care in an Era of Highly Active Anti-Retroviral Therapy for All HIV-1-Infected Individuals. Open Forum Infectious Diseases, 2016, 3, .	0.4	0

#	ARTICLE	IF	CITATIONS
91	A Multifaceted Approach to Self-Reported Antimicrobial Allergy Delabeling Is Possible With a Multidisciplinary Team Initiative. <i>Infectious Diseases in Clinical Practice</i> , 2017, 25, 116-117.	0.1	0
92	186A Pilot Study Profiling Frailty and Ageing in a Population of Older Adults Living with Human Immunodeficiency Virus (HIV). <i>Age and Ageing</i> , 2018, 47, v13-v60.	0.7	0
93	FRI-245-Improvement in cognitive impairment following 12 weeks of aerobic exercise in individuals with non-cirrhotic, chronic hepatitis C. <i>Journal of Hepatology</i> , 2019, 70, e501-e502.	1.8	0
94	Changing Disease Epidemiology to Inform Expanded Coronavirus Disease 2019 Testing. <i>Clinical Infectious Diseases</i> , 2021, 73, 351-352.	2.9	0
95	Pneumococcal vaccine for preventing <i>Streptococcus pneumoniae</i> infection in HIV-positive individuals. <i>The Cochrane Library</i> , 2021, 2021, .	1.5	0
96	Beyond consumption: a qualitative investigation of hospital clinician attitudes to receiving feedback on antimicrobial prescribing quality. <i>Antimicrobial Stewardship &amp; Healthcare Epidemiology</i> , 2022, 2, .	0.2	0
97	Title is missing!. , 2020, 15, e0240784.		0
98	Title is missing!. , 2020, 15, e0240784.		0
99	Title is missing!. , 2020, 15, e0240784.		0
100	Title is missing!. , 2020, 15, e0240784.		0
101	Title is missing!. , 2020, 15, e0240784.		0
102	Title is missing!. , 2020, 15, e0240784.		0